← Trials/Trial dossier/NCT02140983

LGT

CompletedPhase 1

Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes

Lead sponsor

Stanford University

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Prediabetes / glucose intolerance

Key I/E criterion

•BMI 27-37

Primary endpoints

•Cognitive Outcomes•Postprandial glucose

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02140983

Org study ID25076

Timeline

Milestones

Study first posted2014-05-16estimated

Last update posted2018-01-25actual

Study start2013-08actual (month precision)

Primary completion2017-02actual (month precision)

Study completion2017-02actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Prediabetes / glucose intolerance

Eligibility

Who can enroll

Minimum age50 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Subjects will be men and women between the ages of 50 and 70 yrs of age, with a BMI of 27 to 37 kg/m2 and at least 12 yrs of education.

•All subjects will be medically stable (i.e. no uncontrolled or poorly controlled medical illnesses), cognitively-intact as defined by Mini Mental Status Exam (MMSE) score of > 27, and will have adequate visual and auditory acuity to allow for cognitive testing.

•Metabolic function will be determined as impaired fasting glucose 100-125 mg/dL and/or impaired 2-hr glucose concentration 140-199 and <200mg/dL on 75-g oral glucose challenge.

•Also, half of all subjects will have a family history of dementia.

Exclusion criteria

•Diagnosis of possible or probable AD, MCI, or any other dementia; evidence of cognitive decline by MMSE score of <27 or self-reported significant decline in memory within the past year (per the Memory Function Questionnaire) (MFQ)

•History of Type I or Type II diabetes, or fasting plasma glucose > 126 mg/dL

•History of significant CVD or myocardial infarction; unstable cerebrovascular or pulmonary disease, gallstones, pancreatitis or cancer, multiple endocrine neoplasia (MEN) untreated hypothyroidism, unstable or untreated hypertension, anemia as determined by hematocrit < 30%

•Abnormal renal clearance as determined by the serum creatinine ³ 1.5 mg/d, hepatic dysfunction as determined by ALT > 2 times the upper limit of normal

•Presence of medications known to affect insulin action or insulin secretion

•Premature birth (which may affect MRI findings), history of neurological disorder (ischemic attacks, carotid bruits, or lacunes upon MRI scan), or evidence of neurologic or other physical illness that could produce cognitive deterioration; use of any drug that may significantly affect the OGTT results or cognitive testing results (specifically: cs)

•Drug or alcohol abuse or dependence within the past 6 months, positive urine toxicology screen for illicit substances at eligibility screening, history of mental illness, with the exception of past mood disorder, or evidence of acute depression as determined by a 17-item Hamilton Depression Rating Scale (HDRS-17) score of 8 or more.

•Participants with history of mood disorder must be in remission for at least 6 months prior to study entry.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Other clinical outcomes

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

OGTT

Time frame:Change from Baseline to 3 months

Postprandial glucose

change from baseline, improvement

Other clinical outcomes

1 endpoint

Primary/protocol endpoint

Cognitive Outcomes

Time frame:Change from Baseline to 3 months

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.